SNB 2023 Zürich
| Reference number | |
| Coordinator | CombiGene AB |
| Funding from Vinnova | SEK 10 612 |
| Project duration | March 2023 - March 2023 |
| Status | Completed |
| Venture | 2023-00007-en |
Important results from the project
Objective: To establish contact with new Life Science investors as well as with "Big Pharma" companies. In addition, to follow up already established contacts. Results: Several important investor contacts were followed up and a couple of new ones were established. No for us interesting "Big Pharma" companies participated.
Expected long term effects
I identified and established contact with new potential investors and also had the opportunity to update investors we already have contact with.
Approach and implementation
I traveled to Zurich on 29/3, participated on 30/3 in partnering activities and presented CombiGene to approx. 75-100 employees. There were also good opportunities to listen to other company presentations and to network. Return trip on 31/3. Very well planned and executed event.